The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Marcellomycin     methyl(1R,2R,4S)-4- [(2S,4S,5S,6S)-5-[(2R...

Synonyms: Rhodirubin E, CHEMBL508628, CCRIS 2263, LS-93904, AR-1J6263, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Marcellomycin


High impact information on Marcellomycin


Biological context of Marcellomycin


Anatomical context of Marcellomycin


Associations of Marcellomycin with other chemical compounds


Analytical, diagnostic and therapeutic context of Marcellomycin

  • In conjunction with two phase I clinical trials, we have investigated the pharmacokinetics of marcellomycin (MCM), a new class II anthracycline antibiotic, in nine patients with normal renal and hepatic functions and no third-space fluid accumulation [8].
  • Marcellomycin is a new anthracycline that was proposed for clinical trials on the basis of experimental data suggesting reduced potential for hematologic and cardiac toxicity as compared to conventional anthracyclines [9].


  1. Structure-activity relationships for the induction of differentiation of HL-60 human acute promyelocytic leukemia cells by anthracyclines. Schwartz, E.L., Sartorelli, A.C. Cancer Res. (1982) [Pubmed]
  2. Evaluation of some anthracycline antibiotics in an in vivo model for studying drug-induced human leukemia cell differentiation. Schwartz, E.L., Brown, B.J., Nierenburg, M., Marsh, J.C., Sartorelli, A.C. Cancer Res. (1983) [Pubmed]
  3. Inhibition of the RNA polymerase-catalyzed synthesis of RNA by marcellomycin. Preferential interference of the inhibitor with the stabilization of the ternary promoter-RNA polymerase-nascent RNA complex. Kriebardis, T., Aktipis, S. J. Biol. Chem. (1988) [Pubmed]
  4. A phase I trial of marcellomycin with a weekly dose schedule. Joss, R.A., Kaplan, S., Goldhirsch, A., Varini, M., Brunner, K.W., Cavalli, F. European journal of cancer & clinical oncology. (1983) [Pubmed]
  5. Inhibition of glycoprotein biosynthesis by the inducers of HL-60 cell differentiation, aclacinomycin A and marcellomycin. Morin, M.J., Sartorelli, A.C. Cancer Res. (1984) [Pubmed]
  6. Tumorigenicity in vivo and induction of mutagenesis and DNA repair in vitro by aclacinomycin A and marcellomycin: structure-activity relationship and predictive value of short-term tests. Westendorf, J., Marquardt, H., Ketkar, M.B., Mohr, U., Marquardt, H. Cancer Res. (1983) [Pubmed]
  7. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A. Schaefer, A., Boldt, J., Westendorf, J., Steinheider, G., Marquardt, H. Biochem. Pharmacol. (1988) [Pubmed]
  8. Human pharmacokinetics of marcellomycin. Dodion, P., Rozencweig, M., Nicaise, C., Watthieu, M., Tamburini, J.M., Riggs, C.E., Bachur, N.R. Cancer Chemother. Pharmacol. (1985) [Pubmed]
  9. Clinical phase I trial of marcellomycin with a single-dose schedule. Nicaise, C., Rozencweig, M., de Marneffe, M., Crespeigne, N., Dodion, P., Piccart, M., Sculier, J.P., Lenaz, L., Kenis, Y. European journal of cancer & clinical oncology. (1983) [Pubmed]
  10. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents. Schurig, J.E., Schlein, A., Florczyk, A.P., Farwell, A.R., Bradner, W.T. Exp. Hematol. (1985) [Pubmed]
  11. Equilibrium binding of four anthracyclines to nucleic acids: thermodynamic properties and sequence selectivity. Barceló, F., Miró, A. Int. J. Biol. Macromol. (1991) [Pubmed]
  12. The antitumor effects of anthracyclines. II. The stereospecificity of the carbomethoxy group at position 10 of the class II anthracycline molecule. DuVernay, V.H., Eubanks, D., Perales, R., Prestayko, A.W., Crooke, S.T. Mol. Pharmacol. (1982) [Pubmed]
WikiGenes - Universities